Healthcare
ProMIS Neurosciences, Inc.(PMN)
Live Price
Offline$10.54
+1.54% today
1Y Change
-10.30%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -922.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProMIS Neurosciences, Inc. (PMN) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $10.54 and down 10.3% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -922.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -922.2%, free cash flow -103345.2% with operating margin 0.0% and ROIC 3.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PMN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -922.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -1.8% | -2.2% | -8.7% |
2026 Mar 25, 2026 | +11.8% | -4.5% | -18.0% | -31.4% |
2025 Nov 12, 2025 | -60.0% | -4.9% | +2.4% | -14.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PMN Max Drawdown
-75.86%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PMN and SPY.
Company Overview
ProMIS Neurosciences, Inc.
NASDAQ Capital Market
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
- Leadership
- Neil K. Warma
- IPO Date
- Jan 10, 2007
- Employees
- 7
- Street Address
- 1920 Yonge Street
- Mailing
- Toronto, ON, M4S 3E2
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- 416 847 6898
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -922.2%
- Free Cash Flow
- -103345.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -933.6%
- ROIC
- 3.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.88
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.